Positive Effect of Lecithin-Based Delivery Form of Curcuma and Boswellia Extracts on Irritable Bowel Syndrome After COVID-19 Infection.

Background: Post-COVID-19 irritable bowel syndrome (PCIBS) is a frequent finding and is frequently associated with enteral dysbiosis. This pilot study compared the effects of extracts from curcuma and boswellia on PCIBS and irritable bowel syndrome (IBS) in individuals who had never had a COVID-19 infection (controls). Methods: A total of 16 subjects with PCIBS and 28 controls with evidence of IBS gastrointestinal symptoms and with enteral dysbiosis were recruited and supplemented for 30 days with sunflower-lecithin-based formulations of extracts of Curcuma longa (500 mg) and Boswellia serrata (150 mg) b.i.d. and with low-FODMAP diet. Abdominal bloating, abdominal pain, enteral dysbiosis (as increased urinary indican), and the global assessment of efficacy (GAE) were evaluated at the end of the study. Results: In both cohorts, intra-cohort changes revealed a statistically significant (p < 0.05) reduction in bloating and abdominal pain. The GAE showed similar and relevant satisfactory rates in both groups. On the contrary, urinary indican values showed a significant decrease only in the IBS group. Conclusions: Supplementation with Curcuma and Boswellia has favorable effects on abdominal bloating and abdominal pain of subjects with PCIBS and with IBS, while enteral dysbiosis is significantly decreased only in patients with IBS. Additional studies are needed to confirm these preliminary findings and to clarify the reasons for the persistence of dysbiosis in PCIBS.